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Abstract This work describes the molecular cloning of a variant 
isoform of the low-affinity levocabastine-sensitive neurotensin 
receptor isolated from mouse brain. Although the corresponding 
mRNA encodes for a 282 amino acid protein unable to bind 
neurotensin after transient transfection in COS-7 cells, this non-
functional neurotensin receptor is expressed in cerebral neocor-
tex, cerebellum, olfactory bulb, striatum and hypothalamus with 
a level similar to that of the full-length low-affinity neurotensin 
receptor. By contrast, this receptor form is very weakly 
expressed in mesencephalon and absent in the pituitary, but is 
the major product in the spinal cord. 
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1. Introduction 
Among the numerous effects induced after central adminis-
tration of neurotensin (NT) in murine species, hypothermia, 
analgesia and increase in the dopamine turnover and release 
were studied in most detail (for review, see [1]). The recently 
developed non-peptidic antagonist SR48692 [2] was shown to 
be an efficient blocker of the NT-induced modulation of the 
dopaminergic systems via the high-affinity NT receptor 
(NTRH) cloned from the rat brain [3] and from the human 
colonic carcinoma HT29 cell line [4]. By contrast, SR48692 
failed to antagonize NT-induced hypothermia and analgesia 
in mouse and rat [5], likely suggesting that other types of NT 
receptors (cloned and/or not yet identified) could be impli-
cated in these effects. The cloning of cDNAs encoding the 
low-affinity levocabastine-sensitive NT receptor (NTRL) 
from mouse and rat brain [6,7] was recently described. This 
new NT receptor type is pharmacologically distinct from the 
NTRH and also belongs to the family of G-protein-coupled 
receptors identified by their seven hydrophobic domains. This 
receptor family is characterized by the frequent occurrence of 
several subtypes for each natural ligand. An increasing num-
ber of G-protein-coupled receptor subtypes are also expressed 
under the form of spliced variants with variable parts of the 
amino acid sequence modified. Most of these variant isoforms 
such as the somatostatin receptor type 2b [8] remain func-
tional by keeping part of the receptor molecule that is neces-
sary for expression of the binding activity. By contrast, some 
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of these variant forms have lost their ability to bind the nat-
ural ligand either because they have lost typical transmem-
brane-spanning domains as described for the non-functional 
dopamine D3 receptor [9] or because several transmembrane-
spanning domains have been deleted as observed for variants 
of the human growth hormone-releasing hormone receptor 
[10]. 
In the present work, we demonstrate the existence of a 
NTRL variant isoform that has been isolated by high-strin-
gency screening of a mouse brain cDNA library. This variant 
form was characterized by total sequencing and RT-PCR ex-
periments performed on several mouse tissues and brain re-
gions. The deletion of 181 bp, possibly generated by alterna-
tive splicing, induced a frame shift which prematurely 
introduced a stop codon. The translation product of this iso-
form mRNA is a protein of 282 amino acid residues, instead 
of 417 for the long mRNA form, in which the last two trans-
membrane domains have been lost. This protein failed to bind 
NT after transient expression in COS-7 cells, although the 
corresponding mRNA was expressed in several brain areas. 
2. Materials and methods 
2.1. Materials 
Neurotensin was purchased from Peninsula Laboratories. 125I-Tyr3-
NT was prepared and purified as previously described [11]. The ex-
pression vector pcDNA3 was from Invitrogen. Dulbecco's modified 
Eagle's medium and fetal calf serum (FCS) were from Life. Genta-
mycin, 1-10-phenanthroline were from Sigma. FCS was from Boeh-
ringer Mannheim. Oligonucleotides and restriction endonucleases 
were purchased from Eurogentec. 32P-dATP, 35S-Met were from 
ICN Pharmaceutical. 
2.2. cDNA cloning and expression of the NTRL variant 
The mouse brain cDNA library was constructed as initially de-
scribed [6]. High-stringency screening was performed by hybridization 
with a randomly primed, 32P-dATP-labeled probe corresponding to 
the total open reading frame of the cDNA encoding mouse NTRL [6]. 
Hybridization and filter washing were carried out at 68°C under pre-
viously described conditions [12]. One of the isolated clones, bearing 
5' and 3' ends identical to the cDNA encoding the functional 
mNTRL (1.55 kb), was only 1.35 kb long. The total nucleotide se-
quence of this clone was determined in both strands by using the Abi-
prime DNA sequencing kit (Applied Biosystems, Foster City, CA). 
The 1.35 kb EcoRl-Apal fragment of the variant NTRL cDNA 
was subcloned into the eukaryotic expression vector pcDNA3 (Invi-
trogen) containing the cytomegalovirus promotor and the neomycin 
resistance gene as a selective marker. 
Transient transfections were performed with 5 μg of recombinant 
pcDNA3 plasmid by the DEAE-dextran precipitation method [13] 
onto semiconfluent COS-7 cells grown in 100 mm cell culture dishes. 
Binding experiments were performed 60 h after transfection. 
Binding experiments were carried out on freshly prepared cell mem-
brane homogenates as described previously [14]. Cell membranes 
(50 μg) were incubated in 250 μΐ of 50 mM Tris-HCl, pH 7.5, contain-
ing 0.1% bovine serum albumin and 0.8 mM 1-10-phenanthroline 
(binding buffer) with increasing concentrations of 125I-Tyr3-NT 
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(100 Ci/mmol) from 1 to 10 nM. Non-specific binding was measured 
in parallel incubations containing 1 μΜ unlabeled NT. After 20 min 
at 25°C, incubation media were filtered through cellulose acetate fil-
ters (Sartorius, Bohemia, NY). Filters were rinsed twice with 2 ml of 
ice-cold binding buffer and counted in a Packard γ-counter, with a 
80% counting efficiency. 
2.3. RT-PCR and Southern blot analysis 
Total RNAs were extracted from different mouse central nervous 
system (CNS) regions using the Chomczynski and Sacchi method [15]. 
The reverse transcription reactions were performed with 2 μg of total 
RNAs by using the 'Reverse Transcription System' kit (Promega) and 
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Fig. 1. Nucleotide and predicted amino acid sequences of the mouse 
NTRL. A: The longer nucleotide sequence is shown as previously 
reported [6]. The 181 bp sequence truncated in the short form is 
boxed. The deduced amino acid sequence of the C-terminus of the 
truncated isoform is shown under the previous sequence. Putative 
transmembrane segments are underlined and numbered I through 
VII. B: Comparison of the consensus nucleotide sequence of 5' and 
3' vertebrate splicing sites (uper case lettering) with the sequence at 
the junction of the truncated protein (lower case lettering). Nucleo-
tides matching the consensus sequence are underlined. Y, pyrimi-
dines; R, purines; N, any nucleotide. 
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Fig. 2. Schematic representation of the NTRL and nfNTRL 
cDNAs. The primers and the hybridization probes are positioned. 
The corresponding coding regions are boxed. 
a 15-mer oligo-dT primer. The resulting single-stranded DNA was 
used as template for PCR amplifications. The oligonucleotides used 
(5'-AAACGTGCTGGTCTCCTTCGT-3' and 5'-TGGGGTTTCTT-
GGGGATCCC-3') are flanking the region where the deletion oc-
curred and allow the amplification of a fragment of the receptor 
cDNA from bases 654-1257 in the sequence previously reported [6]. 
The predicted size of amplified fragments was 604 bp for mNTRL and 
423 bp for the variant form. PCR products were analyzed on a 2% 
agarose gel. In some cases, the gel was denaturated in 0.5 M NaOH, 
1 M NaCl twice for 15 min and neutralized in 20XSSC and DNA 
fragments were transfered onto a Hybond-N nylon membrane (Amer-
sham) under 20 X SSC overnight. Transfered DNAs were finally fixed 
by exposure to UV. 
The prehybridization was performed at 65°C for 2 h in 5XDen-
hardt's solution, 6 X SSC, 0.2% SDS and 100 μg/ml denaturated sal-
mon sperm DNA. Hybridization was performed in the same buffer 
using 32P-labeled specific probes. Probe 1 which is theoretically able to 
label the two variant products was prepared by PCR using oligonu-
cleotides described above and the recombinant plasmid containing the 
full-length NTRL as template. Probe 2 which is specific for the greater 
fragment corresponding to the native NTR was prepared from the 
first probe by enzymatic restriction with BstXI and BstYI, which 
led to a 110 bp fragment corresponding to a part of the region missing 
in the variant form. This fragment was purified from a 3% low geling 
temperature agarose gel and centrifugation through glass fiber. The 
probes were labeled with 32P-dCTP by using the 'Nonaprimer labeling 
kit' from Appligene. The labeled probes were purified by G50 gel 
filtration and used for hybridization after denaturation for 5 min at 
95°C. The hybridization was carried out overnight at 65°C with 
1 X 106 cpm/ml of labeled probes. Washing steps were carried out as 
follows: 2x15 min with 0.2 SSC; 0.1% SDS at room temperature and 
2X 15 min with 0.1 SSC; 0.1% SDS at 65°C. 
3. Results 
3.1. Molecular cloning, sequencing and identification of the 
variant form of NTRL 
A mouse brain c D N A library consisting of 5 x l 0 5 clones 
was screened by hybridization with a c D N A probe corre-
sponding to the open reading frame of the mouse N T R L 
c D N A clone under high-stringency conditions. F r o m seven 
positive clones corresponding either to partial or total 
N T R L cDNA, one clone, whose restriction analysis revealed 
5' and 3 ' ends identical to those of the full-length N T R L 
cDNA, clearly appeared shorter (1.37 kb). Nucleic acid se-
quence analysis demonstrated that this c D N A clone was iden-
tical to that of N T R L except that a 181 bp fragment corre-
sponding to nucleotides 747-927 of the previously reported 
c D N A sequence was missing (Fig. 1A). This deletion causes 
a shift of the reading frame in the corresponding C-terminal 
amino acid sequence, resulting in a truncated N T R which was 
135 amino acid shorter than the full length form and which 
contained 42 different amino acids in its C-terminus (Fig. 1A). 
Note that the C-terminal sequence of the short N T R L form, 
which could be intracellular, contains nine Ser and six Thr 
residues. The previously described mouse N T R L is a protein 
of 417 amino acids, whereas the shorter form is constituted of 
282 amino acid residues. As shown in Fig. IB, the nucleotide 
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Fig. 3. Hydrophobicity plot of the two NTRL isoforms. Hydropho-
bicity of predicted amino acid sequences of longer (A) and shorter 
(B) NTRL was determined by the method of Kyte and Doolittle 
[17]. Stretches of hydrophobic regions are numbered. Inserts: Trans-
membrane domains and extra- and intracytoplasmic loops of the re-
spective proteins are schematically represented. 
sequence of the 5' end of the truncated portion was found to 
share high homology with the consensus sequence of verte-
brate splice acceptor sites [16]. Hydrophobicity analysis of the 
predicted amino acid sequences clearly indicated that the C-
terminus of the truncated NTRL missed the two C-terminal 
transmembrane domains VI and VII (Fig. 2) [17]. As pre-
dicted from this observation, COS-7 cells transfection of the 
recombinant pcDNA3 plasmid encoding the shorter NTRL 
led to membrane preparations totally devoid of 125I-Tyr3-
NT binding (results not shown). 
To demonstrate that this shorter form is actually expressed 
in the mouse brain, and particularly to eliminate the possibil-
ity of an artifactual recombination during the construction of 
the library, the presence of both long and short receptor 
mRNAs in the mouse brain was examined by RT-PCR ex-
periments. Amplification products obtained by PCR are vis-
ualized in Fig. 3A (lane 2) where two bands with predicted 
sizes of 604 and 423 bp were actually amplified in the whole 
brain. The identity of these PCR products was further con-
firmed by Southern blot analysis, using either a common 
radiolabeled cDNA probe (probe 1, 604 bp), or a radiolabeled 
probe specific of the longer form (probe 2, 110 bp). Labeling 
of the two bands in Fig. 3B, and of only the 604 bp band in 
Fig. 3C, corresponded to the expected situation in which both 
PCR products beared common nucleotide sequence, the short-
er form lacking a 181 bp fragment as compared to the long 
form. 
To eliminate the possible obtention of an artifactual prod-
uct generated in mouse brain either by reverse transcription 
or by PCR reactions, RNAs were extracted from COS-7 cells 
transiently transfected with the full-length NTRL cDNA, 
then, the single strand obtained by reverse transcription was 
used with the same primers for PCR amplification. Only the 
largest product (604 bp) was detected (Fig. 5, lane 9). 
The expression of mRNA encoding two NTRL isoforms in 
different mouse CNS structures and in the pituitary was ex-
amined (Fig. 4). The two forms were clearly expressed in the 
neocortex, the cerebellum, the striatum, the olfactory bulb 
and the hypothalamus (lanes 1, 2, 4, 6, and 8). A higher 
expression of the full-length form was observed in the mesen-
cephalon (lane 3) whereas the spinal cord almost exclusively 
expressed the truncated form (lane 5). By contrast, the pitui-
tary appeared to be devoid of NTRL isoforms (lane 7). 
4. Discussion 
This work describes the existence of a variant form of the 
mouse NTRL. The corresponding receptor cDNA is identical 
to the full-length NTRL, except for a 181 nucleotide deletion. 
This deletion leads to a shift of the reading frame which 
changes the C-terminal amino acid sequence leading to a pro-
tein of 282 residues. The resulting protein is devoid of the last 
two hydrophobic domains VI and VII and fails to specifically 
bind 125I-Tyr3-NT after transient expression in COS-7 cells. 
We know from coupled transcription-translation experiments 
that the cDNA encoding this truncated receptor is able to 
produce a protein of 31 kDa as predicted from the amino 
acid sequence (result not shown). However, the loss of 135 
residues, representing almost one-third of the NTRL, could 
alter the correct addressing to the cell membrane during ex-
pression experiments. 
Two possibilities could account for the production of this 
non-functional NTRL (nfNTRL) mRNA. (1) It could result 
from alternative splicing of the NTRL primary transcript. (2) 
The variant NTRL cDNA could represent the transcript from 
an unidentified duplicated gene carrying a deletion. Indeed, if 
the 181 nucleotides sequence (missing in nfNTRL) is defined 
as an intron, expression of the corresponding mRNA must be 
regulated by alternative splicing of the NTRL primary tran-
script. The consensus sequence for 5' splice sites correctly 
matches with this putative intron at its 5' end (Fig. IB), but 
the 3' cleavage site is CA:N whereas the highly conserved 
sequence of 3' splice sites is AG:N [16]. Thus, in the case of 
an alternative splicing, the 3' end of the intron would be 
unusual. Careful sequencing of several clones isolated from 
mouse brain by RT-PCR confirms the sequence of the trun-
cated isoform with a 181-nucleotide-long deletion. Therefore, 
the possibility of a gene duplication with a deletion represents 
the most probable explanation of the existence of such a 
truncated receptor form. Further chromosomal location using 
specific probes will definitively answer the question. 
A growing series of truncated G-protein-coupled receptors 
has been described. Some of these truncations did not modify 
Fig. 4. Expression of NTRL isoforms in the mouse brain. RT-PCR 
experiments are shown in A. Lane 1: primers with H2O; lane 2: to-
tal mouse brain. B,C: Southern blot of the same gel hybridized 
with either probe 1 (B) or probe 2 (C). 
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Fig. 5. Expression of mRNAs encoding the two NTRL isoforms in 
eight mouse central nervous system structures and in the pituitary. 
PCRs were performed on RNAs reverse transcribed by using pri-
mers flanking the truncated portion. The sizes of the two PCR 
products are 604 and 423 bp, respectively. As an internal standard, 
GAPDH mRNA was also amplified (target size: 600 bp). Lane 1: 
neocortex; lane 2: cerebellum; lane 3: mesencephalon; lane 4: stria-
tum; lane 5: spinal cord; lane 6; olfactory bulb; lane 7: pituitary; 
lane 8: hypothalamus; lane 9: COS-7 cells transfected with the full-
length NTRL cDNA. 
sion of full-length and truncated receptors could consist in the 
modulat ion by the truncated form of potential intracellular 
events induced by the full-length N T R L . Indeed, the C-term-
inal sequence of the truncated N T R L which bears 42 different 
amino acid residues strongly resembles classical C-terminus of 
G-protein-coupled receptors rich in Ser and Thr residues [20]. 
For example, this protein, if correctly inserted into the cell 
plasma membrane, could play a role in the regulation of in-
ternalization of either the N T R L or a structurally related 
receptor. The functional or pathological importance of the 
truncated N T R L remains to be elucidated. However, it is 
important to be aware of the existence of this new family of 
truncated receptors whose physiological activity is unknown. 
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